X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

Usual Pharma Compliance Issues Noted In FDA Warning Letters

Content Team by Content Team
25th August 2022
in FDA Approvals, News
Usual Pharma Compliance Issues Noted In FDA Warning Letters

According to a study of the reasons behind warning letters sent by the US Food and Drug Administration Center for Drug Evaluation and Research and Center for Devices and Radiological Health between 2010 and 2020, poor current good manufacturing practise (cGMP) compliance and misbranding were the most frequent citations.

Deficiencies in process validation, documentation practises, and quality control were the three major types of breaches that made up the cGMP letters, accounting for 26%, 21%, and 15% of the warning letters, respectively.

FDA warning letters can be a valuable source of information for researching and analysing infractions that take place during the production of pharmaceuticals. Through the ability to recognise and address any problems, these studies can also assist businesses in preparing for impending examinations.

When breaches are discovered during an audit, an FDA warning letter is sent to the manufacturer. However, this only occurs if the firm’s response to the flaws detailed in a form 483 is inadequate. The business is required to take the necessary actions to address the faults specified in the warning letter after receiving it.

Researchers identified not just the main reasons for warning letters but also important areas that FDA investigators may concentrate on when inspecting pharmaceutical producers in a study that was published in the Journal of Pharmaceutical Innovation. The authors located and examined 3777 warning letters from CDER and CDRH in total. In general, the most significant cGMP violations were validation, documentation, and quality control.

The researchers did observe that between 2015 and 2020, pharmaceutical producers received more warning letters than medical device makers. Misbranding and poor cGMP compliance were the main causes of this.

The production, buildings and equipment, laboratory control, materials systems, and packaging and labelling systems are five manufacturing systems that are connected to the FDA’s quality system, which is the heart of its six-system inspection model, according to the authors.

The researchers reached the conclusion that pharmaceutical companies should put their attention toward creating efficient quality management systems that regulate the entire production process, quality control, employee training, and documentation practises, as well as keeping up with guidelines and standards to make sure they are aware of the regulatory agency’s expectations, in order to have a successful inspection. Experts advise businesses to create a compliance monitoring check list and get ready to take corrective action if necessary.

Previous Post

CRISIL Expects Indian Pharma Sales To Climb 7%-9% In FY23

Next Post

Forecasting Biopharma Contract Manufacturing Trends In 2022

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post
Integrity Bio Announces Newly Validated Biotech Manufacturing Line

Forecasting Biopharma Contract Manufacturing Trends In 2022

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In